12 Imaging Core Labs for Clinical Trials in 2026

An imaging core lab gives a multi-site clinical trial a single, standardized source of image acquisition, quality control, and expert central reading, replacing the variability of local radiologist interpretation with a consistent methodology applied across every site and every scan. An imaging core lab might specialize in a therapeutic area like oncology, neurology, or musculoskeletal disease, or in a specific technology such as AI-driven quantitative analysis or a particular imaging modality. For Sponsors and CROs evaluating an imaging core lab, the choice often comes down to therapeutic depth, the breadth of validated imaging biomarkers a vendor can support, and how heavily a study will lean on automated versus expert-reader analysis.

The labs below, presented in no particular order, span a range of therapeutic and technical specialties. Between them they cover gastrointestinal and neurological imaging core labs, oncology-focused imaging CROs, AI-powered quantitative platforms, and body composition and liver disease imaging biomarkers.

Alimentiv

Alimentiv operates a gastrointestinal-focused imaging core lab built around its Clinical Imaging Management System (CIMS), which the company states established the gold standard for centralized endoscopy reading in inflammatory bowel disease research. Originally founded as Robarts Clinical Trials in 1986 at the Robarts Research Institute in London, Ontario, the company rebranded as Alimentiv in 2020 and now supports GI clinical trials across more than 60 countries. Alimentiv's imaging work spans centralized endoscopy, histopathology, and noninvasive modalities including intestinal ultrasound and MR enterography.

Image Analysis Group (IAG)

Image Analysis Group operates as a global imaging CRO built around its DYNAMIKA cloud-native platform, which standardizes image collection, quality control, and central review across global clinical trial sites. Founded in 2007 and headquartered in London, England, the company states it has supported more than 700 global clinical trials and maintains a specialist focus on neuro-oncology, oncology, and immunology imaging. In 2026 IAG partnered with HeartcoR Solutions to combine imaging and cardiac safety core lab services, and separately partnered with Better Medicine to bring AI-powered whole-body oncology imaging into its DYNAMIKA workflows.

Imaging Endpoints

Imaging Endpoints operates as an imaging research and core laboratory specializing in oncology, and the company states it is the world's largest oncology-focused imaging CRO, with experience spanning hundreds of successful trials across all phases of development. Based in Scottsdale, Arizona with additional offices in Cambridge, Massachusetts, London, Hyderabad, Basel, Leiden, and Shanghai, the company is affiliated with HonorHealth and Scottsdale Medical Imaging. Imaging Endpoints has built proprietary radiomics and AI capabilities into its imaging core lab services, including a patented medical imaging system.

Median Technologies

Median Technologies provides imaging CRO services for oncology trials alongside iBiopsy, its AI-powered imaging platform for developing software as a medical device, and the company launched Imaging Lab in 2022 to bring iBiopsy's data mining and radiomics technologies into its core lab imaging services. Founded in 2002 and based in Sophia Antipolis, France, with subsidiaries in the US and Shanghai, the company is listed on the Euronext Growth market in Paris. Median has since expanded iBiopsy into lung cancer screening and liver disease software as a medical device, including an FDA regulatory submission for its lung cancer screening tool.

Medical Metrics (MMI)

Medical Metrics operates a full-service, ISO 9001-certified imaging core lab focused on musculoskeletal, spine, cardiovascular, neurological, and ENT clinical trials, and the company states it has been involved in approximately 80% of regulated spine trials run in the US over the past two decades. Founded in 2000 and based in Houston, Texas, the company holds a 510(k)-cleared image management platform and has released its own FDA-cleared software as a medical device, SpineCAMP, for spine imaging assessment. MMI has supported more than 700 global clinical trials since its founding.

Medical Image Analysis Center (MIAC)

MIAC operates as an imaging CRO specializing in brain and spinal cord neuroimaging, with particular depth in multiple sclerosis research, providing tailor-made data analysis pipelines built to Swiss quality standards. Originally founded in 1995 as an academic corporation of Basel University Hospital, the company is based in Basel, Switzerland and remains embedded in national and international neuroimaging research networks. MIAC has supported the design and validation of software as a medical device alongside its centralized MRI analysis services for international clinical trials.

Perspectum

Perspectum developed LiverMultiScan, an FDA-cleared and CE-marked multiparametric MRI technology that quantifies liver fat, fibrosis, and inflammation without requiring an invasive liver biopsy, alongside a proprietary cT1 biomarker for hepatic fibro-inflammatory disease. Founded in 2012 as a spin-out from the University of Oxford, the company maintains offices in the UK, US, Portugal, and Singapore. A 2022 health economic study by NHS England's Oxford Academic Health Science Network found LiverMultiScan to be a cost-effective alternative to liver biopsy for monitoring autoimmune hepatitis.

QMENTA

QMENTA, legally known as Mint Labs Inc., provides a cloud-based medical imaging platform purpose-built for AI-powered neuroimaging in clinical trials, and the company states more than 16 million imaging files have been managed across more than 250 sites for clients including the NIH, Bayer, and ICON. Headquartered in Boston with a European office in Barcelona, the company launched Central Review in 2026, an end-to-end platform covering site upload, blinded multi-reader assessment, and locked database export built for the FDA's Real-Time Clinical Trials initiative. QMENTA's technology has contributed to research supporting revisions of the McDonald Criteria for multiple sclerosis diagnosis.

QYNAPSE

QYNAPSE develops QyScore, an FDA-cleared and CE-marked AI-powered neuroimaging software platform that automates quantification of brain imaging markers for neurological disease diagnosis and clinical trial monitoring. Founded in Paris in 2015 as a spin-off from the CATI consortium of neuroimaging research laboratories, the company also markets QyPredict, a research-use tool that generates a cognitive decline risk score to improve patient selection in Alzheimer's trials. QYNAPSE expanded its AI platform through the 2020 acquisition of Canada's TRUE POSITIVE MEDICAL DEVICES and maintains offices in Paris, Boston, and Canada.

AMRA Medical

AMRA Medical provides MRI-based body composition analysis, measuring fat and muscle biomarkers such as visceral adipose tissue, muscle volume, and liver fat fraction to support metabolic and musculoskeletal clinical trials. Founded in 2010 as a spin-off from Linköping University's Center for Medical Image Science and Visualization, the company is headquartered in Linköping, Sweden. AMRA's visceral adipose tissue biomarker was validated through the FNIH's NIMBLE consortium in 2023, and its whole-body MRI methodology has supported natural history studies in rare muscle diseases including facioscapulohumeral muscular dystrophy.

Cardialysis

Cardialysis operates a cardiovascular imaging core lab spanning echocardiography, cardiac MRI, cardiac CT, quantitative coronary angiography, intravascular ultrasound, and ECG-Holter analysis, and the company states its echocardiography core lab alone has centrally analyzed more than 40,000 echocardiograms. Founded in 1983 by cardiologists at the Thoraxcenter of Erasmus Medical Center in Rotterdam, the company also launched and maintains the globally used SYNTAX score website and operates a dedicated Structural Heart Core Lab supporting transcatheter therapy trials such as TAVR. Cardialysis has monitored more than 1,400 clinical sites and 200,000 patients across its four-decade history.

Bioxydyn

Bioxydyn provides quantitative MRI biomarker services as a specialist imaging CRO, covering oncology, respiratory, neurology, liver, and drug safety applications through techniques such as diffusion MRI, dynamic contrast-enhanced MRI, and MR spectroscopy. Founded in 2009 and based in Manchester, England, the company states its work on a liver MRI biomarker led to its acceptance into the FDA's biomarker qualification program, and it has partnered with NVision Imaging Technologies to advance hyperpolarized metabolic imaging in oncology. Bioxydyn's leadership includes former AstraZeneca Chief Scientist John Waterton, who also holds a professorship in translational imaging at the University of Manchester.

Explore the full Imaging landscape

The companies above represent a portion of a much larger field.

Diligent's platform includes over 230 Imaging Core Lab Vendors, with Vendor qualification data available on demand. Book a demo to explore Diligent's full vendor discovery database.

This article is intended as an informational overview of vendors operating in this space. Inclusion on this list does not constitute an endorsement, recommendation, or qualification by Diligent.